Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

ENHERTU® (fam-trastuzumab deruxtecan-nxki) reduced the risk of disease recurrence or death by 53% vs. T-DM1 in patients with high-risk HER2-positive early breast cancer following neoadjuvant therapy in DESTINY-Breast05 Phase III trial

October 18, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 Phase III trial

October 18, 2025

TEZSPIRE approved in the US for chronic rhinosinusitis with nasal polyps

October 17, 2025

DATROWAY® Plus Rilvegostomig Showed Promising Tumor Responses in Patients with Metastatic Urothelial Cancer in TROPION-PanTumor03 Phase 2 Trial

October 17, 2025

IMFINZI® (durvalumab) regimen reduced the risk of disease recurrence or death by 32% in high-risk non-muscle-invasive bladder cancer in the POTOMAC Phase III trial

October 17, 2025

IMFINZI® (durvalumab)-based regimen reduced the risk of death by 22% in early gastric cancer vs. chemotherapy alone in MATTERHORN Phase III trial

October 17, 2025

AstraZeneca unveils expanded manufacturing facility in Texas

October 15, 2025

AstraZeneca furthers ambition to redefine cancer care with first data from four major pivotal trials at ESMO

October 13, 2025

Agreement with US Govt to lower medicine prices

October 13, 2025

AstraZeneca plans to increase investment and scope of its Virginia manufacturing facility to $4.5 billion, creating 3,600 new jobs

October 9, 2025

Baxdrostat met the primary endpoint in Bax24 Phase III trial in patients with resistant hypertension

October 7, 2025

Baxdrostat met primary endpoint in Bax24 Ph3 trial

October 7, 2025

Algen Biotechnologies Announces Multi-Target Partnership to Advance AI-Powered Drug Discovery in Immunology with AstraZeneca

October 6, 2025

DATROWAY® (datopotamab deruxtecan-dlnk) improved OS and PFS in TROPION-Breast02

October 6, 2025

DATROWAY® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival as First-Line Therapy for Patients with Metastatic Triple Negative Breast Cancer for Whom Immunotherapy Was Not an Option in TROPION-Breast02

October 6, 2025

Datroway improved OS and PFS in TROPION-Breast02

October 6, 2025

Thermo Fisher Scientific Announces R&D Partnership with AstraZeneca BioVentureHub

October 1, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated highly statistically significant and clinically meaningful improvement in invasive disease-free survival vs. T-DM1 in DESTINY-Breast05 Phase III trial

September 29, 2025

Enhertu improved IDFS in early BC in DB-05

September 29, 2025

AZN harmonises listing structure

September 29, 2025

AstraZeneca launches direct-to-consumer platform to expand access to medications for US patients, including those living with chronic conditions

September 26, 2025

ENHERTU® (fam-trastuzumab deruxtecan-nxki) plus pertuzumab granted Priority Review in the US as 1st-line treatment for patients with HER2-positive metastatic breast cancer

September 24, 2025

Koselugo recommended for EU approval

September 22, 2025

Tezspire Recommended for Approval in EU for CRSwNP

September 22, 2025

AIRSUPRA® (albuterol/budesonide) US prescribing information updated to reflect the statistically significant severe exacerbation risk reduction in patients with mild asthma compared with albuterol

September 18, 2025

SAPHNELO self-administration TULIP-SC Phase III trial meets primary endpoint in patients with systemic lupus erythematosus based on an interim analysis

September 17, 2025

Saphnelo met primary endpoint in TULIP-SC

September 17, 2025

Update on RESOLUTE Phase III trial

September 17, 2025

ENHERTU® Type II Variation Application Validated in the EU for Previously Treated Patients with HER2 Positive Metastatic Solid Tumors

September 11, 2025

Tive Partners with AstraZeneca to Provide a Temperature Tracker for FluMist Home Delivery Program

September 9, 2025

H1 and Q2 2025 results

July 29, 2025

Gefurulimab nanobody met Phase III endpoints

July 24, 2025

AstraZeneca plans to invest $50bn in the US

July 22, 2025

Update on anselamimab in AL amyloidosis

July 16, 2025

Baxdrostat met primary endpt in BaxHTN PhIII trial

July 14, 2025

Imfinzi approved in the EU for bladder cancer

July 4, 2025

Datroway approved in US for EGFRm lung cancer

June 24, 2025

AstraZeneca enters into collaboration with CSPC

June 13, 2025

Fixed-duration Calquence approved in EU for 1L CLL

June 6, 2025

Imfinzi recommended in EU for bladder cancer

May 27, 2025

Acquisition of EsoBiotec completed

May 20, 2025

Imfinzi improved DFS in early bladder cancer

May 9, 2025

Enhertu improved pCR in early-stage breast cancer

May 7, 2025

Calquence combination approved in EU for 1L MCL

May 6, 2025

Breztri met primary endpoints in Ph3 asthma trials

May 2, 2025

Fixed-duration Calquence recommended in EU for CLL

April 29, 2025

Update on CAPItello-280 Phase III trial

April 29, 2025

1st Quarter Results

April 29, 2025

Enhertu combination improved PFS in 1L HER2+ mBC

April 22, 2025

Result of AGM

April 11, 2025

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 242 decks. Every deck is listed under its year.